SBIR Phase I: Development of a biological adhesive for the fixation and integration of cartilage implants

SBIR 第一阶段：开发用于软骨植入物固定和整合的生物粘合剂

• 批准号: 2036583
• 负责人: Wendy Brown
• 金额: $ 25.6万
• 依托单位: CARTILAGE INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-02-15 至 2023-01-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2036583&HistoricalAwards=false
• 关键词: SBIR; Phase; Development; biological; adhesive

The broader impact of this Small Business Innovation Research (SBIR) Phase I project is that it will develop a novel biological glue to enhance knee cartilage healing. Injuries (e.g., sports-related) or extensive use leads to deterioration because cartilage does not heal. For repair implants, including transplants and engineered grafts, securing the implant into the damaged cartilage and ensuring its growth are critical for successful healing. The proposed project will develop an advanced adhesive with live cells and other biological additives to actively encourage integration of the implant into adjacent cartilage for accelerated healing. The proposed project will advance a biological glue to enhances cartilage healing. Specifically, this project will increase the stickiness and thickness of the glue to make its properties comparable or superior to fibrin glue, the commercially available standard. This project will: (1) explore biological additives to the active cells and molecular cartilage components already present in the biological glue and compare performance with the fibrin standard; (2) examine the biological glue’s ability to secure a cartilage implant into damaged native cartilage over four weeks in a laboratory model; and (3) assess the glue durability and healing. Ultimately, it is anticipated that the glue developed in this project will promote the fixation and integration of cartilage implants into native cartilage.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I阶段项目的更广泛影响是，它将开发出一种新型的生物学胶水来增强膝盖软骨愈合。伤害（例如，与运动有关的）或大量使用导致确定，因为软骨无法愈合。对于维修凹痕，包括移植物和工程移植物，将植入物固定到受损的软骨中，并确保其生长对于成功的康复至关重要。拟议的项目将开发具有活细胞和其他生物添加剂的先进粘合剂，以积极鼓励将植入物整合到相邻软骨中以加速愈合。拟议的项目将推进生物胶水以增强软骨愈合。具体而言，该项目将增加胶水的粘性和厚度，使其性能可与纤维蛋白胶（（可商购的标准）相提并论。该项目将：（1）探索生物胶中已经存在的活性细胞和分子软骨成分的生物添加剂，并将性能与纤维蛋白标准进行比较； （2）检查生物胶在实验室模型中在四个星期内将软骨植入物将软骨植入物固定到损害的天然软骨中的能力； （3）评估胶水耐用性和愈合。最终，预计该项目中开发的胶水将促进软骨将固定在本地软骨中的固定和整合。该奖项反映了NSF的法定任务，并通过使用该基金会的知识分子和更广泛的影响审查标准来通过评估来诚实地获得支持。